National Alliance for Eye and Vision Research
Advocacy Center
Become an Advocate for Vision Research
Eye Fact Center
Press Center
Newsletters
Spread the Word
Tell Your Story
Link to Our Site
Resources and Links
Privacy Policy
Site Map
NAEVR in Action
About the Alliance National Eye Institute Contact Us
Become an Advocate for Vision Research - Join the Action List
Speak Up for Eye and Vision Research
Enter Your Zip Code   
 

 

Vision Community Unites to Observe World Glaucoma Day on Capitol Hill

To recognize the second annual World Glaucoma Day (WGD) on March 12, the Association for Eye and Vision Research (AEVR) sponsored a March 10 Capitol Hill briefing to educate Members of Congress and their staffs. The event was timely, as the Senate was passing the Fiscal Year (FY) 2009 Omnibus appropriations bill, which increases National Eye Institute (NEI) funding by $21.4 million over FY2008. That annual spending increase, coupled with the $175 million in two-year funding for NEI research from the American Recovery and Reinvestment Act of 2009, means nearly $200 million more for vision research.

In introducing the briefing, AEVR Executive Director James Jorkasky read from a March 6 statement issued by the NEI for WGD in which its Director Paul Sieving, M.D., Ph.D., noted that NEI currently spends $65 million in support of 168 glaucoma studies, including the newly initiated NEI Glaucoma Human genetics collaBORation, known as NEIGHBOR, through which seven U.S. research teams will lead genetic studies of the disease.

The featured speakers included Murray Fingeret, O.D., F.A.A.O., (Brooklyn/St. Albans Campus, Department of Veterans Administration New York Harbor Health Care System), who spoke about the incidence and burden of the disease, and Rohit Varma, M.D., M.P.H., (Doheny Eye Institute, University of Southern California), who spoke about research and treatments. Both speakers had participated in a March13-14, 2008, joint NEI/Food and Drug Administration (FDA) Glaucoma Endpoints meeting at which researchers acknowledged that glaucoma is a complex, neurodegenerative disease in which detectable changes within the eye may not progress linearly or in concert with functional changes, that is, vision loss.

AEVR was joined by the American Glaucoma Society (AGS), the Association for Research in Vision and Ophthalmology (ARVO), the Glaucoma Research Foundation (GRF), and The Glaucoma Foundation (TGF) in sponsoring the briefing. TGF President and Chief Executive Officer Scott Christensen announced that his organization and the Congressional Glaucoma Caucus would assist the World Glaucoma Association with a March 11 glaucoma screening event at the United Nations in New York City, conducted by a dozen eye specialists from The New York Eye and Ear Infirmary (NYEE). The Capitol Hill and UN events are just two of the many hundreds of events being held around the globe during the week in recognition of World Glaucoma Day.

Murray Fingeret, O.D., F.A.A.O
Murray Fingeret, O.D., F.A.A.O. "Glaucoma prevalence in the U.S. is 2.2 million individuals and approaching 60 million individuals globally. However, anywhere from 50-75 percent of individuals with glaucoma are undiagnosed, as it often has no symptoms until vision is lost."
Rohit Varma, M.D., Ph.D
Rohit Varma, M.D., M.P.H.. "Researchers are studying the genetic basis of glaucoma and using genes to determine a potential response to medical treatment, that is, prior to treating, knowing how a drug is going to work."
Left to right: The featured speakers with Cong. John Boozman (R-AR)
Left to right: The featured speakers with Cong. John Boozman (R-AR), who sponsored the Military Eye Trauma Treatment Act that created within the Department of Defense the Vision Center of Excellence and Military Eye Trauma Injury Registry
The Glaucoma Foundationís Scott Christensen
The Glaucoma Foundationís Scott Christensen announces a glaucoma screening event to be held on March 11 at the United Nations in New York City